Literature DB >> 27027416

Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.

Zachary C Dietch1, Therese M Duane2, Charles H Cook3, Patrick J O'Neill4, Reza Askari5, Lena M Napolitano6, Nicholas Namias7, Christopher M Watson8, Daniel L Dent9, Brandy L Edwards1, Puja M Shah1, Christopher A Guidry1, Stephen W Davies1, Rhett N Willis1, Robert G Sawyer1,10.   

Abstract

BACKGROUND: Obesity and commonly associated comorbidities are known risk factors for the development of infections. However, the intensity and duration of antimicrobial treatment are rarely conditioned on body mass index (BMI). In particular, the influence of obesity on failure of antimicrobial treatment for intra-abdominal infection (IAI) remains unknown. We hypothesized that obesity is associated with recurrent infectious complications in patients treated for IAI.
METHODS: Five hundred eighteen patients randomized to treatment in the Surgical Infection Society Study to Optimize Peritoneal Infection Therapy (STOP-IT) trial were evaluated. Patients were stratified by obese (BMI ≥30) versus non-obese (BMI≥30) status. Descriptive comparisons were performed using Chi-square test, Fisher exact test, or Wilcoxon rank-sum tests as appropriate. Multivariable logistic regression using a priori selected variables was performed to assess the independent association between obesity and treatment failure in patients with IAI.
RESULTS: Overall, 198 (38.3%) of patients were obese (BMI ≥30) versus 319 (61.7%) who were non-obese. Mean antibiotic d and total hospital d were similar between both groups. Unadjusted outcomes of surgical site infection (9.1% vs. 6.9%, p = 0.36), recurrent intra-abdominal infection (16.2% vs. 13.8, p = 0.46), death (1.0% vs. 0.9%, p = 1.0), and a composite of all complications (25.3% vs. 19.8%, p = 0.14) were also similar between both groups. After controlling for appropriate demographics, comorbidities, severity of illness, treatment group, and duration of antimicrobial therapy, obesity was not independently associated with treatment failure (c-statistic: 0.64).
CONCLUSIONS: Obesity is not associated with antimicrobial treatment failure among patients with IAI. These results suggest that obesity may not independently influence the need for longer duration of antimicrobial therapy in treatment of IAI versus non-obese patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27027416      PMCID: PMC4960476          DOI: 10.1089/sur.2015.213

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  24 in total

1.  Dosing of piperacillin/tazobactam in a morbidly obese patient.

Authors:  Hanna Deman; Jan Verhaegen; Ludo Willems; Isabel Spriet
Journal:  J Antimicrob Chemother       Date:  2011-11-30       Impact factor: 5.790

2.  Trial of short-course antimicrobial therapy for intraabdominal infection.

Authors:  Robert G Sawyer; Jeffrey A Claridge; Avery B Nathens; Ori D Rotstein; Therese M Duane; Heather L Evans; Charles H Cook; Patrick J O'Neill; John E Mazuski; Reza Askari; Mark A Wilson; Lena M Napolitano; Nicholas Namias; Preston R Miller; E Patchen Dellinger; Christopher M Watson; Raul Coimbra; Daniel L Dent; Stephen F Lowry; Christine S Cocanour; Michaela A West; Kaysie L Banton; William G Cheadle; Pamela A Lipsett; Christopher A Guidry; Kimberley Popovsky
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

3.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 4.  Critical care of the bariatric patient.

Authors:  Fredric M Pieracci; Philip S Barie; Alfons Pomp
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

5.  Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.

Authors:  K Chiba; M Tsuchiya; J Kato; K Ochi; Z Kawa; T Ishizaki
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  The obesity paradox in surgical intensive care patients with peritonitis.

Authors:  Stefan Utzolino; Christian M Ditzel; Peter K Baier; Ulrich T Hopt; Magnus F Kaffarnik
Journal:  J Crit Care       Date:  2014-06-05       Impact factor: 3.425

7.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.

Authors:  Diane Newman; Marc H Scheetz; Oluwadamilola A Adeyemi; Mauro Montevecchi; David P Nicolau; Gary A Noskin; Michael J Postelnick
Journal:  Ann Pharmacother       Date:  2007-08-28       Impact factor: 3.154

9.  Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.

Authors:  R L Yost; H Derendorf
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

10.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

View more
  2 in total

1.  Operative management of acute abdomen after bariatric surgery in the emergency setting: the OBA guidelines.

Authors:  Belinda De Simone; Elie Chouillard; Almino C Ramos; Gianfranco Donatelli; Tadeja Pintar; Rahul Gupta; Federica Renzi; Kamal Mahawar; Brijesh Madhok; Stefano Maccatrozzo; Fikri M Abu-Zidan; Ernest E Moore; Dieter G Weber; Federico Coccolini; Salomone Di Saverio; Andrew Kirkpatrick; Vishal G Shelat; Francesco Amico; Emmanouil Pikoulis; Marco Ceresoli; Joseph M Galante; Imtiaz Wani; Nicola De' Angelis; Andreas Hecker; Gabriele Sganga; Edward Tan; Zsolt J Balogh; Miklosh Bala; Raul Coimbra; Dimitrios Damaskos; Luca Ansaloni; Massimo Sartelli; Nikolaos Parasas; Yoram Kluger; Elias Chahine; Vanni Agnoletti; Gustavo Fraga; Walter L Biffl; Fausto Catena
Journal:  World J Emerg Surg       Date:  2022-09-27       Impact factor: 8.165

2.  Impact of bodyweight-adjusted antimicrobial prophylaxis on surgical-site infection rates.

Authors:  L Salm; W R Marti; D J Stekhoven; C Kindler; M Von Strauss; E Mujagic; W P Weber
Journal:  BJS Open       Date:  2021-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.